We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Better idea

23 April 2012 By Robert Cyran

The industry is off to one of its best years in a decade. As Pfizer’s sale of its nutrition business for $12 bln suggests, Big Pharma is forgoing mega-deals for smaller, targeted acquisitions of innovators like Ardea and Amylin, who are needed to refill empty drug pipelines.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)